Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:53:44 EST Fri 23 Jan 2026
Enter Symbol
or Name
USA
CA



Q:TTIPF - THIOGENESIS THERAPEUTICS CORP - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TTIPF - Qnot subscribed0.5834    2.58  0.0016Nov 2509:0115 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-23 09:01U:TTIPFNews ReleaseThiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
2026-01-13 09:01U:TTIPFNews ReleaseThiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
2026-01-05 09:02U:TTIPFNews ReleaseThiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar
2025-12-09 08:35U:TTIPFNews ReleaseThiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11th
2025-11-24 09:02U:TTIPFNews ReleaseThiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
2025-11-04 09:01U:TTIPFNews ReleaseThiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
2025-10-03 16:01U:TTIPFNews ReleaseThiogenesis Announces Extension to Investor Relations Agreement
2025-09-11 09:01U:TTIPFNews ReleaseThiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update
2025-06-25 09:02U:TTIPFNews ReleaseThiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
2025-06-20 09:02U:TTIPFNews ReleaseThiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference
2025-06-17 09:01U:TTIPFNews ReleaseThiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
2025-06-12 10:02U:TTIPFNews ReleaseThiogenesis Announces Grant of Stock Options
2025-06-11 09:01U:TTIPFNews ReleaseThiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum
2025-05-14 09:02U:TTIPFNews ReleaseThiogenesis Initiates Phase 2 Clinical Trial in Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS")
2025-02-20 09:01U:TTIPFNews ReleaseThiogenesis Announces European Consulting and Investor Relations Agreement
2025-02-12 09:01U:TTIPFNews ReleaseThiogenesis Announces Commencement of OTCQX Trading in the U.S.
2025-02-12 07:00U:TTIPFNews ReleaseOTC Markets Group Welcomes Thiogenesis Therapeutics, Corp. to OTCQX
2025-01-27 09:01U:TTIPFNews ReleaseThiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS